One objective underlying development of these guidelines was to identify research gaps regarding the management of cancer treatment–related hot flashes.
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
The level of control of acute-phase CIV in pediatric patients was lower in this study than has been reported for adult patients; control of delayed-phase CIV is also poor.
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
Prescription drug monitoring programs that aim to prevent opioid misuse may be affecting patients with cancer who need pain management.
Although olanzapine shows promise as a treatment for chronic nausea and vomiting in patients with advanced cancer, larger studies are needed.
A prospective study demonstrated this treatment is an option for patients undergoing chemoradiation for gynecologic cancers who are at risk of late-onset CINV or noncompliance with oral therapy.
A randomized study determined the efficacy of adding peppermint essential oil to a cool wash cloth to ease nausea associated with chemotherapy.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.